SCHEMBL5832695

SCHEMBL5832695

CN1C2CCC1CN(c1ccc3c(c1)Cc1ccccc1-3)CC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
OPRM1 P35372 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
PDK2 Q15119 1/20 0.40
HTT P42858 1/20 0.39
DRD2 P14416 3/20 0.38
DRD4 P21917 3/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DRD3 P35462 1/20 0.36
CYP17A1 P05093 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5833414 0.95 SLC6A2 (0.42) SLC6A2SLC6A4SLC6A3OPRM1OPRK1
SCHEMBL5465191 0.77 HTR3A (0.54) SLC6A4SLC6A3DRD4
SCHEMBL5832396 0.76 CHRNA7 (0.46) ALDH1A1MAPT
SCHEMBL3055453 0.76 MBTD1 (0.51) SLC6A2SLC6A3DRD2DRD4MAPT
SCHEMBL28492509 0.74 NPC1 (0.52) SLC6A2SLC6A4PDK2HTTDRD2
SCHEMBL5832829 0.74 HRH3 (0.44) SLC6A2SLC6A4SLC6A3ALDH1A1HPGD
SCHEMBL3057878 0.72 NOTUM (0.54) SLC6A2SLC6A4HTTLMNAMAPT
SCHEMBL5832796 0.72 HTR3A (0.51) SLC6A2SLC6A4SLC6A3DRD4
SCHEMBL5832318 0.71 NOTUM (0.56) SLC6A4HTT
SCHEMBL5832888 0.71 MBTD1 (0.40) SLC6A4SLC6A3DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060699-B2 Aryl and heteroaryl diazabicycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2006-06-13 US disclosed
EP-1301514-B1 ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE NEUROSEARCH AS (DK) 2005-01-26 EP disclosed
CN-1185233-C Aryl and heteroaryl diazabicycloalkanes, their preparation and use NEUROSEARCH AS (DK) 2005-01-19 CN disclosed
US-20030176416-A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2003-09-18 US disclosed
CN-1440411-A Aryl and heteroaryl diazabicycloalkanes, their preparation and use NEUROSEARCH AS (DK) 2003-09-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176416-A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use CHRNA7, CHRNA5, CHRNA2 SLC6A2 57/4885SLC6A4 153/4885SLC6A3 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.